Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
Purpose
This phase II trial investigates how well biomarkers on PET/CT imaging drive early discontinuation of anti-PD-1 therapy in patients with stage IIIB-IV melanoma that cannot be removed by surgery (unresectable). Anti-PD-1 therapy has become a standard therapy option for patients with unresectable melanoma. This trial is being done to determine if doctors can safely shorten the use of standard of care anti-PD1 therapy for melanoma by using biomarkers seen on PET/CT imaging and tumor biopsy.
Conditions
- Advanced Melanoma
- Clinical Stage III Cutaneous Melanoma AJCC v8
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Melanoma of Unknown Primary
- Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
- Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
- Pathologic Stage IIID Cutaneous Melanoma AJCC v8
- Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Unresectable Acral Lentiginous Melanoma
- Unresectable Melanoma
- Unresectable Mucosal Melanoma
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- STEP 0 PRE-REGISTRATION INCLUSION CRITERIA - Patient must have active advanced melanoma, defined as unresectable stage IIIB-IV by American Joint Committee on Cancer (AJCC) 8th edition - Patient must have melanoma originating from cutaneous, acral-lentiginous, or mucosal primary sites. Patients with melanoma of unknown primary site are eligible. Patients must not have melanoma from an ocular primary site - Patient must have had measurable disease by immune related Response Evaluation Criteria in Solid Tumors (imRECIST) prior to start of initial anti-PD-1 therapy - Patient must be actively receiving standard of care anti-PD-1 therapy, currently be 52 weeks (+/- 2 weeks) from start of anti-PD-1 therapy, and have not experienced a toxicity that prevents them from continuing on therapy. Permitted systemic anti-PD-1 therapy regimens include: - Nivolumab 240 mg IV every (Q)2weeks or 480 mg IV Q4weeks - Pembrolizumab 200 mg IV Q3weeks or 400 mg IV Q6weeks - Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg IV Q3weeks induction x 4 doses, followed by nivolumab 240 mg IV Q2weeks or 480 mg IV Q4weeks maintenance - Nivolumab 3 mg/kg plus Ipilimumab 1 mg/kg IV Q3weeks induction x 4 doses, followed by nivolumab 240 mg IV Q2weeks or 480 mg IV Q4weeks maintenance - Pembrolizumab 2 mg/kg (or 200 mg flat dose) plus Ipilimumab 1 mg/kg IV Q3weeks induction x 4 doses, followed by pembrolizumab 200 mg IV Q3weeks or 400 mg IV Q6weeks maintenance - Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 - Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. Patients with detectable viral loads are excluded as it is unclear if these patients have a low risk of melanoma progression off anti-PD-1 treatment - For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated - Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load - Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial - Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better - Patient must have experienced complete response, partial response, or stable disease on restaging CT scans by imRECIST that is maintained on restaging scans obtained at week 52 (+/- 2 weeks) from start of initial anti-PD-1 therapy - Patient must have completed an FDG-PET/CT scan at week 52 (+/- 2 weeks) from start of initial anti-PD-1 therapy - Patients with PET/CT positive for hypermetabolic lesions: If a core needle, punch or excisional biopsy and pathological review of a representative lesion was not performed prior to pre-registration (Step 0) must either: - Be amenable to undergo a biopsy. Patient must not be on anticoagulation therapy or, if on anti-coagulation therapy, patient must be able to hold treatment for a biopsy procedure (core needle, punch or excisional biopsy). Anti-coagulation therapy is defined as low molecular weight heparin, warfarin, factor Xa inhibitor, or direct thrombin inhibitor - Have documentation of inability to perform the biopsy due to feasibility or safety concerns - Leukocytes >= 3,000/mcL (obtained =< 4 weeks prior to protocol registration) - Absolute neutrophil count >= 1,500/mcL (obtained =< 4 weeks prior to protocol registration) - Platelets >= 100,000/mcL (obtained =< 4 weeks prior to protocol registration) - Total bilirubin =< institutional upper limit of normal (ULN) (patients with history of Gilbert's syndrome are permitted to have a total bilirubin > 1.5 x institutional ULN) (obtained =< 4 weeks prior to protocol registration) - Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN (obtained =< 4 weeks prior to protocol registration) - Creatinine =< 1.5 x institutional ULN (obtained =< 4 weeks prior to protocol registration) - STEP 1 REGISTRATION INCLUSION CRITERIA - Patient met all eligibility criteria outlined above - Patient must register to Step 1 within 4 weeks of registration to Step 0 - Patients must meet one of the following criteria: - Patient had no positive hypermetabolic lesions on the week 52 FDG-PET/CT. - Patients with positive hypermetabolic lesion(s) on the week 52 FDG-PET/CT (positive hypermetabolic = standard uptake volume [SUV] > pooled mediastinal blood), one of the following must have occurred: - A representative lesion was biopsied (core needle, punch or excisional biopsy) within 14 days of registration to Step 0 and subsequent pathology review performed to determine the presence or absence of viable tumor - Documentation is present that the patient is not able to undergo biopsy of a hypermetabolic lesion due to feasibility or safety concerns, i.e., the lesion location that is not amenable to biopsy
Exclusion Criteria
- STEP 0 PRE-REGISTRATION EXCLUSION CRITERIA - Patient must not be receiving concurrent anti-tumor therapies in addition to the standard of care anti-PD-1 regimens. Patients who are receiving bisphosphonates and RANKL inhibitors for management of bone metastases are eligible - Patient must not have brain metastases - Women must not be pregnant or breast-feeding due to potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the anti-PD-1 regimens being used. All females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy. A female of childbearing potential is defined as any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months) - Women of childbearing potential and sexually active males must not conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse from the time of study registration and continuing until at least 5 months after the last dose of anti-PD-1 treatment for female patients and for at least 7 months after the last dose of anti-PD-1 treatment for male patients who are sexually active with a women of childbearing potential (WOCBP)
Study Design
- Phase
- Phase 2
- Study Type
- Interventional
- Allocation
- Non-Randomized
- Intervention Model
- Sequential Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Experimental Arm A (active surveillance) |
Patients with a negative FDG-PET/CT scan or a positive FDG-PET/CT scan but with a negative biopsy for viable tumor discontinue the anti-PD-1 therapy and undergo active surveillance. |
|
Active Comparator Arm B (nivolumab, pembrolizumab, ipilimumab) |
Patients with a positive FDG-PET/CT scan and positive biopsy for viable tumor or a positive FDG-PET/CT scan and biopsy not performed continue their standard of care anti-PD-1 therapy for 12 months in the absence of disease progression or unacceptable toxicity. |
|
Other Standard of Care (nivolumab, pembrolizumab, ipilimumab) |
Patients continue their standard of care anti-PD-1 therapy. Treatment may consist of the following regimens: 1) nivolumab IV over 30 minutes Q2W or Q4W; 2) pembrolizumab IV over 30 minutes Q3W or Q6W; 3) nivolumab IV over 30 minutes and ipilimumab IV Q3W for 4 doses followed by nivolumab IV over 30 minutes Q2W or Q4W; or 4) pembrolizumab IV over 30 minutes and ipilimumab IV Q3W for 4 doses followed by pembrolizumab IV over 30 minutes Q3W or Q6W. Treatment continues until 52 weeks from start of standard of care anti-PD-1 therapy in the absence of disease progression or unacceptable toxicity. |
|
Recruiting Locations
Fairhope, Alabama 36532
Site Public Contact
251-435-4584
Mobile, Alabama 36607
Site Public Contact
251-435-3942
Fairbanks, Alaska 99701
Phoenix, Arizona 85004
Tucson, Arizona 85719
Tucson, Arizona 85719
Fort Smith, Arkansas 72903
Site Public Contact
800-378-9373
Little Rock, Arkansas 72205
Little Rock, Arkansas 72205
Site Public Contact
501-686-8274
Antioch, California 94531
Arroyo Grande, California 93420
Carmichael, California 95608
Carmichael, California 95608
Dublin, California 94568
Site Public Contact
877-642-4691
Elk Grove, California 95758
Fremont, California 94538
Fresno, California 93720
Fresno, California 93720
Los Angeles, California 90025
Los Angeles, California 90048
Site Public Contact
310-423-8965
Merced, California 95340
Modesto, California 95356
Oakland, California 94611
Oakland, California 94611
Rancho Cordova, California 95670
Redwood City, California 94063
Site Public Contact
877-642-4691
Richmond, California 94801
Rocklin, California 95765
Rohnert Park, California 94928
Roseville, California 95661
Roseville, California 95678
Sacramento, California 95814
Sacramento, California 95816
Sacramento, California 95823
Sacramento, California 95823
San Francisco, California 94115
San Jose, California 95119
San Leandro, California 94577
San Luis Obispo, California 93401
San Rafael, California 94903
Santa Clara, California 95051
Santa Maria, California 93444
Santa Rosa, California 95403
South San Francisco, California 94080
South San Francisco, California 94080
Stockton, California 95210
Vacaville, California 95688
Vallejo, California 94589
Walnut Creek, California 94596
Walnut Creek, California 94598
Woodland, California 95695
Aurora, Colorado 80012
Boulder, Colorado 80303
Boulder, Colorado 80304
Centennial, Colorado 80112
Colorado Springs, Colorado 80907
Colorado Springs, Colorado 80907
Colorado Springs, Colorado 80923
Denver, Colorado 80205
Denver, Colorado 80209
Denver, Colorado 80218
Denver, Colorado 80218
Denver, Colorado 80220
Durango, Colorado 81301
Durango, Colorado 81301
Englewood, Colorado 80113
Englewood, Colorado 80113
Lafayette, Colorado 80026
Lakewood, Colorado 80228
Lakewood, Colorado 80228
Littleton, Colorado 80120
Lone Tree, Colorado 80124
Lone Tree, Colorado 80124
Longmont, Colorado 80501
Longmont, Colorado 80501
Pueblo, Colorado 81004
Thornton, Colorado 80260
Washington, District of Columbia 20007
Site Public Contact
202-444-2223
Washington, District of Columbia 20010
Site Public Contact
202-877-8839
Aventura, Florida 33180
Site Public Contact
954-461-2180
Coral Gables, Florida 33146
Site Public Contact
305-243-2647
Deerfield Beach, Florida 33442
Site Public Contact
305-243-2647
Fort Lauderdale, Florida 33308
Miami, Florida 33136
Site Public Contact
305-243-2647
Miami, Florida 33176
Site Public Contact
305-243-2647
Plantation, Florida 33324
Site Public Contact
305-243-2647
Atlanta, Georgia 30322
Site Public Contact
404-778-1868
Atlanta, Georgia 30342
Duluth, Georgia 30096
Lawrenceville, Georgia 30046
Honolulu, Hawaii 96819
Boise, Idaho 83706
Caldwell, Idaho 83605
Coeur d'Alene, Idaho 83814
Emmett, Idaho 83617
Meridian, Idaho 83642
Nampa, Idaho 83687
Post Falls, Idaho 83854
Sandpoint, Idaho 83864
Alton, Illinois 62002
Site Public Contact
618-463-5623
Bloomington, Illinois 61704
Canton, Illinois 61520
Carbondale, Illinois 62902
Carterville, Illinois 62918
Carthage, Illinois 62321
Centralia, Illinois 62801
Centralia, Illinois 62801
Chicago, Illinois 60611
Chicago, Illinois 60612
Site Public Contact
312-355-3046
Decatur, Illinois 62526
Decatur, Illinois 62526
Dixon, Illinois 61021
Site Public Contact
815-285-7800
Effingham, Illinois 62401
Elmhurst, Illinois 60126
Eureka, Illinois 61530
Galesburg, Illinois 61401
Galesburg, Illinois 61401
Site Public Contact
309-344-2831
Kewanee, Illinois 61443
Macomb, Illinois 61455
Mount Vernon, Illinois 62864
Site Public Contact
618-242-4600
Naperville, Illinois 60540
Site Public Contact
630-646-6075
O'Fallon, Illinois 62269
O'Fallon, Illinois 62269
Ottawa, Illinois 61350
Pekin, Illinois 61554
Peoria, Illinois 61615
Peoria, Illinois 61636
Peru, Illinois 61354
Peru, Illinois 61354
Site Public Contact
815-664-4141
Plainfield, Illinois 60585
Princeton, Illinois 61356
Springfield, Illinois 62702
Site Public Contact
217-545-7929
Springfield, Illinois 62702
Site Public Contact
800-444-7541
Springfield, Illinois 62781
Washington, Illinois 61571
Ankeny, Iowa 50023
Site Public Contact
515-282-2921
Carroll, Iowa 51401
Des Moines, Iowa 50309
Site Public Contact
515-241-6727
Des Moines, Iowa 50309
Site Public Contact
515-241-3305
Des Moines, Iowa 50314
Site Public Contact
515-282-2200
Des Moines, Iowa 50316
Site Public Contact
515-241-8704
Fort Dodge, Iowa 50501
Site Public Contact
515-574-8302
West Des Moines, Iowa 50266-7700
Site Public Contact
515-343-1000
Garden City, Kansas 67846
Great Bend, Kansas 67530
Bardstown, Kentucky 40004
Corbin, Kentucky 40701
Lexington, Kentucky 40504
Lexington, Kentucky 40504
Lexington, Kentucky 40509
London, Kentucky 40741
Mount Sterling, Kentucky 40353
Paducah, Kentucky 42003
Baltimore, Maryland 21237
Site Public Contact
443-777-7364
Boston, Massachusetts 02118
Site Public Contact
617-638-8265
Adrian, Michigan 49221
Site Public Contact
517-265-0116
Ann Arbor, Michigan 48106
Battle Creek, Michigan 49017
Brighton, Michigan 48114
Brighton, Michigan 48114
Canton, Michigan 48188
Canton, Michigan 48188
Caro, Michigan 48723
Chelsea, Michigan 48118
Chelsea, Michigan 48118
Clarkston, Michigan 48346
Clarkston, Michigan 48346
Detroit, Michigan 48236
Flint, Michigan 48503
Flint, Michigan 48503
Flint, Michigan 48503
Flint, Michigan 48503
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49009
Kalamazoo, Michigan 49048
Lansing, Michigan 48912
Livonia, Michigan 48154
Marlette, Michigan 48453
Monroe, Michigan 48162
Site Public Contact
800-444-3561
Muskegon, Michigan 49444
Niles, Michigan 49120
Site Public Contact
616-391-1230
Norton Shores, Michigan 49444
Pontiac, Michigan 48341
Pontiac, Michigan 48341
Pontiac, Michigan 48341
Pontiac, Michigan 48341
Reed City, Michigan 49677
Saginaw, Michigan 48601
Saginaw, Michigan 48604
Saint Joseph, Michigan 49085
Saint Joseph, Michigan 49085
Tawas City, Michigan 48764
Traverse City, Michigan 49684
Warren, Michigan 48093
West Branch, Michigan 48661
Wyoming, Michigan 49519
Ypsilanti, Michigan 48106
Ypsilanti, Michigan 48197
Aitkin, Minnesota 56431
Baxter, Minnesota 56425
Site Public Contact
218-828-2880
Bemidji, Minnesota 56601
Brainerd, Minnesota 56401
Deer River, Minnesota 56636
Detroit Lakes, Minnesota 56501
Duluth, Minnesota 55805
Duluth, Minnesota 55805
Duluth, Minnesota 55805
Ely, Minnesota 55731
Site Public Contact
218-365-7900
Fosston, Minnesota 56542
Hibbing, Minnesota 55746
Site Public Contact
218-786-3308
International Falls, Minnesota 56649
Site Public Contact
218-283-9431
Moose Lake, Minnesota 55767
Site Public Contact
218-485-4481
Park Rapids, Minnesota 56470
Saint Cloud, Minnesota 56303
Sandstone, Minnesota 55072
Thief River Falls, Minnesota 56701
Site Public Contact
605-312-3320
Virginia, Minnesota 55792
Worthington, Minnesota 56187
Site Public Contact
605-312-3320
Ballwin, Missouri 63011
Site Public Contact
314-251-7058
Bolivar, Missouri 65613
Branson, Missouri 65616
Site Public Contact
417-269-4520
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
Site Public Contact
573-651-5550
Farmington, Missouri 63640
Site Public Contact
314-996-5569
Joplin, Missouri 64804
Joplin, Missouri 64804
Osage Beach, Missouri 65065
Rolla, Missouri 65401
Rolla, Missouri 65401
Site Public Contact
573-458-6379
Saint Joseph, Missouri 64506
Saint Louis, Missouri 63109
Site Public Contact
314-353-1870
Saint Louis, Missouri 63128
Saint Louis, Missouri 63131
Site Public Contact
314-996-5569
Saint Louis, Missouri 63141
Site Public Contact
314-251-7066
Sainte Genevieve, Missouri 63670
Site Public Contact
314-996-5569
Springfield, Missouri 65804
Site Public Contact
417-269-4520
Springfield, Missouri 65807
Site Public Contact
417-269-4520
Sullivan, Missouri 63080
Site Public Contact
314-996-5569
Sunset Hills, Missouri 63127
Site Public Contact
314-996-5569
Washington, Missouri 63090
Site Public Contact
636-390-1600
Anaconda, Montana 59711
Billings, Montana 59101
Bozeman, Montana 59715
Great Falls, Montana 59405
Great Falls, Montana 59405
Kalispell, Montana 59901
Missoula, Montana 59804
Kearney, Nebraska 68847
Omaha, Nebraska 68122
Omaha, Nebraska 68124
Omaha, Nebraska 68130
Omaha, Nebraska 68131
Hackensack, New Jersey 07601
Site Public Contact
551-996-2897
Middletown, New Jersey 07748
Site Public Contact
212-639-7592
Montvale, New Jersey 07645
Site Public Contact
212-639-7592
Neptune, New Jersey 07753
Site Public Contact
732-776-4240
Red Bank, New Jersey 07701
Site Public Contact
732-530-2382
Albuquerque, New Mexico 87106
Glens Falls, New York 12801
Site Public Contact
518-926-6700
Harrison, New York 10604
Site Public Contact
212-639-7592
New York, New York 10016
Cary, North Carolina 27518
Site Public Contact
919-781-7070
Chapel Hill, North Carolina 27599
Durham, North Carolina 27710
Site Public Contact
888-275-3853
Greenville, North Carolina 27834
Raleigh, North Carolina 27607
Site Public Contact
919-785-4878
Raleigh, North Carolina 27609
Site Public Contact
919-862-5400
Bismarck, North Dakota 58501
Fargo, North Dakota 58103
Fargo, North Dakota 58103
Site Public Contact
701-234-6161
Fargo, North Dakota 58103
Site Public Contact
605-312-3320
Fargo, North Dakota 58104
Site Public Contact
800-437-4010
Fargo, North Dakota 58122
Fargo, North Dakota 58122
Jamestown, North Dakota 58401
Avon, Ohio 44011
Site Public Contact
800-641-2422
Beachwood, Ohio 44122
Belpre, Ohio 45714
Centerville, Ohio 45459
Chillicothe, Ohio 45601
Cincinnati, Ohio 45219
Cincinnati, Ohio 45220
Cincinnati, Ohio 45242
Cincinnati, Ohio 45247
Cincinnati, Ohio 45255
Cleveland, Ohio 44106
Columbus, Ohio 43210
Columbus, Ohio 43213
Columbus, Ohio 43219
Columbus, Ohio 43222
Dayton, Ohio 45409
Dayton, Ohio 45409
Site Public Contact
937-276-8320
Dayton, Ohio 45415
Franklin, Ohio 45005-1066
Gahanna, Ohio 43230
Greenville, Ohio 45331
Site Public Contact
937-569-7515
Grove City, Ohio 43123
Grove City, Ohio 43123
Lancaster, Ohio 43130
Lima, Ohio 45801
Marietta, Ohio 45750
Marysville, Ohio 43040
Maumee, Ohio 43537
Mount Vernon, Ohio 43050
New Albany, Ohio 43054
Newark, Ohio 43055
Newark, Ohio 43055
Perrysburg, Ohio 43551
Portsmouth, Ohio 45662
Sandusky, Ohio 44870
Springfield, Ohio 45504
Springfield, Ohio 45504
Toledo, Ohio 43608
Toledo, Ohio 43623
Toledo, Ohio 43623
Toledo, Ohio 43623
Site Public Contact
800-444-3561
Troy, Ohio 45373
West Chester, Ohio 45069
Westerville, Ohio 43081
Wilmington, Ohio 45177
Zanesville, Ohio 43701
Oklahoma City, Oklahoma 73120
Site Public Contact
405-752-3402
Baker City, Oregon 97814
Ontario, Oregon 97914
Allentown, Pennsylvania 18103
Bethlehem, Pennsylvania 18017
Danville, Pennsylvania 17822
East Stroudsburg, Pennsylvania 18301
Hazleton, Pennsylvania 18201
Hazleton, Pennsylvania 18201
Lewisburg, Pennsylvania 17837
Pottsville, Pennsylvania 17901
Scranton, Pennsylvania 18510
Wilkes-Barre, Pennsylvania 18711
Willow Grove, Pennsylvania 19090
Gaffney, South Carolina 29341
Greer, South Carolina 29651
Spartanburg, South Carolina 29303
Site Public Contact
864-560-6812
Spartanburg, South Carolina 29303
Spartanburg, South Carolina 29307
Site Public Contact
864-560-6812
Union, South Carolina 29379
Sioux Falls, South Dakota 57104
Sioux Falls, South Dakota 57117-5134
Berlin, Vermont 05602
Site Public Contact
802-225-5400
Burlington, Vermont 05401
Burlington, Vermont 05405
Bremerton, Washington 98310
Port Townsend, Washington 98368
Site Public Contact
360-344-3091
Silverdale, Washington 98383
Ashland, Wisconsin 54806
Ashland, Wisconsin 54806
Chippewa Falls, Wisconsin 54729
Eau Claire, Wisconsin 54701
Hayward, Wisconsin 54843
Ladysmith, Wisconsin 54848
Marshfield, Wisconsin 54449
Milwaukee, Wisconsin 53226
Site Public Contact
414-805-3666
Minocqua, Wisconsin 54548
Mukwonago, Wisconsin 53149
Oconomowoc, Wisconsin 53066
Site Public Contact
262-928-7878
Rice Lake, Wisconsin 54868
Spooner, Wisconsin 54801
Stevens Point, Wisconsin 54482
Superior, Wisconsin 54880
Site Public Contact
701-364-6272
Waukesha, Wisconsin 53188
Site Public Contact
262-928-7632
Waukesha, Wisconsin 53188
Wausau, Wisconsin 54401
Weston, Wisconsin 54476
Wisconsin Rapids, Wisconsin 54494
Cody, Wyoming 82414
Sheridan, Wyoming 82801
More Details
- NCT ID
- NCT04462406
- Status
- Recruiting
- Sponsor
- ECOG-ACRIN Cancer Research Group
Detailed Description
PRIMARY OBJECTIVE: I. To determine the 12 month event free survival (EFS) rate following discontinuation of anti-PD-1 therapy in patients with disease control and negative fludeoxyglucose F-18 (FDG)- positron emission tomography (PET)/computed tomography (CT) scan or biopsy for residual disease after 12 months of anti-PD-1 therapy (Arm A). SECONDARY OBJECTIVES: I. To determine rates of pathologic response in patients with tumor biopsies where positive hypermetabolic activity was present on FDG-PET/CT scan after 12 months of anti-PD-1 therapy (Arm B). II. To determine the overall 24 month EFS. III. To determine overall survival from start of anti-PD-1 therapy. IV. To determine percentage for patients who remain on treatment beyond 12 months because of positive FDG-PET/CT scan and positive biopsy for residual disease (or unable to obtain a biopsy). V. To determine incidence rates of treatment-related adverse events beyond 12 months from start of treatment in patients who discontinue anti-PD-1 therapy at 12 months and in patients who continue anti-PD-1 therapy beyond 12 months (Arm A versus [vs.] Arm B). EXPLORATORY OBJECTIVES: I. To assess agreement in determining FDG-PET/CT positivity between the local site read and central review. II. To determine if metabolic response on serial FDG-PET/CT from pre-therapy to 12 months of anti-PD-1 therapy, as determined centrally by various criteria, is associated with EFS. III. To determine if metabolic response on serial FDG-PET/CT from 12 to 24 months after start of anti-PD-1 therapy, as determined centrally by various criteria, is associated with EFS. BIOMARKER OBJECTIVE: I. To bank tumor samples and peripheral blood for future biomarker studies. OUTLINE: Patients continue their standard of care anti-PD-1 therapy and are then assigned to 1 of 2 arms. STANDARD OF CARE: Treatment may consist of the following regimens: 1) nivolumab intravenously (IV) over 30 minutes every 2 weeks (Q2W) or every 4 weeks (Q4W); 2) pembrolizumab IV over 30 minutes every 3 weeks (Q3W) or every 6 weeks (Q6W); 3) nivolumab IV over 30 minutes and ipilimumab IV Q3W for 4 doses followed by nivolumab IV over 30 minutes Q2W or Q4W; or 4) pembrolizumab IV over 30 minutes and ipilimumab IV Q3W for 4 doses followed by pembrolizumab IV over 30 minutes Q3W or Q6W. Treatment continues until 52 weeks from start of standard of care anti-PD-1 therapy in the absence of disease progression or unacceptable toxicity. ARM A: Patients with a negative FDG-PET/CT scan or a positive FDG-PET/CT scan but with a negative biopsy for viable tumor discontinue the anti-PD-1 therapy and undergo active surveillance. ARM B: Patients with a positive FDG-PET/CT scan and positive biopsy for viable tumor or a positive FDG-PET/CT scan and biopsy not performed continue their standard of care anti-PD-1 therapy for 12 months in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up through week 97 and then every 3 months for up to 5 years.